NEWARK, Calif., Nov. 13, 2019 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief
Executive Officer, will present at two upcoming healthcare investor
conferences in New York.
Presentation details:
Event: Stifel 2019 Healthcare
Conference
Date: Wednesday, Nov. 20
Time: 2:25 p.m. EST
Event: Piper Jaffray 31st Annual
Healthcare Conference
Date: Thursday, Dec. 5
Time: 1:30 p.m. EST
Live and archived audio webcasts of the Stifel and Piper
presentations can be accessed by visiting the Investors page of the
Protagonist Therapeutics website at
http://investors.protagonist-inc.com/.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to transform existing
treatment paradigms for patients with significant unmet medical
needs. PTG-300 is an injectable hepcidin mimetic in development for
the potential treatment of iron overload anemia and related rare
blood diseases including beta-thalassemia and polycythemia vera.
PTG-200 is an oral, gut-restricted interleukin-23 receptor specific
antagonist peptide in Phase 2 clinical development for the
potential treatment of inflammatory bowel disease, with Crohn's
disease as the initial indication. The Company has a worldwide
license and collaboration agreement with Janssen Biotech for the
clinical development of PTG-200. PN-943 is an oral, gut-restricted
alpha-4-beta-7 integrin specific antagonist peptide in clinical
development for the potential treatment of inflammatory bowel
disease, with a Phase 2 ulcerative colitis study expected to
commence in the first half of 2020.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-two-upcoming-healthcare-investor-conferences-300957130.html
SOURCE Protagonist Therapeutics, Inc.